Christopher Ray Aker Sells 38,547 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) VP Christopher Ray Aker sold 38,547 shares of Regulus Therapeutics stock in a transaction on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $48,569.22. Following the sale, the vice president now directly owns 54,634 shares of the company’s stock, valued at approximately $68,838.84. This trade represents a 41.37 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Regulus Therapeutics Stock Up 0.8 %

Shares of RGLS stock opened at $1.28 on Friday. The firm has a market cap of $83.84 million, a price-to-earnings ratio of -1.20 and a beta of 1.60. Regulus Therapeutics Inc. has a 52-week low of $1.08 and a 52-week high of $3.79. The company’s 50 day moving average is $1.52 and its 200 day moving average is $1.58.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Analysts anticipate that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Institutional Trading of Regulus Therapeutics

Several hedge funds have recently modified their holdings of RGLS. Bank of New York Mellon Corp purchased a new position in shares of Regulus Therapeutics in the 2nd quarter worth approximately $352,000. Rhumbline Advisers purchased a new stake in Regulus Therapeutics during the second quarter valued at approximately $136,000. Renaissance Technologies LLC boosted its stake in Regulus Therapeutics by 56.4% in the second quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 42,600 shares in the last quarter. SG Americas Securities LLC purchased a new position in Regulus Therapeutics in the third quarter worth $33,000. Finally, Creative Planning acquired a new position in shares of Regulus Therapeutics during the third quarter worth $26,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a research report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.